Orion OYJ (OTCMKTS:ORINY) Shares Gap Up – Still a Buy?

Shares of Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) gapped up prior to trading on Monday . The stock had previously closed at $35.28, but opened at $36.8425. Orion OYJ shares last traded at $36.8425, with a volume of 100 shares traded.

Analysts Set New Price Targets

ORINY has been the subject of several research analyst reports. Nordea Equity Research upgraded shares of Orion OYJ from a “hold” rating to a “buy” rating in a research note on Monday, October 6th. Zacks Research lowered Orion OYJ from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Orion OYJ Stock Performance

The business has a 50 day moving average of $35.09 and a 200-day moving average of $37.47. The company has a market capitalization of $10.40 billion, a P/E ratio of 29.71 and a beta of 0.06. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.19 and a current ratio of 1.99.

Orion OYJ (OTCMKTS:ORINY) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.40 earnings per share for the quarter. The firm had revenue of $494.69 million for the quarter. Orion OYJ had a return on equity of 31.36% and a net margin of 19.33%. On average, sell-side analysts predict that Orion OYJ Unsponsored ADR will post 1.18 EPS for the current fiscal year.

Orion OYJ Dividend Announcement

The firm also recently announced a dividend, which was paid on Friday, November 7th. Shareholders of record on Friday, October 17th were paid a $0.2418 dividend. This represents a yield of 127.0%. The ex-dividend date was Thursday, October 16th. Orion OYJ’s dividend payout ratio is currently 26.61%.

Orion OYJ Company Profile

Orion Corporation (Orion Oyj) is a Finland-based pharmaceutical company engaged in the research, development, manufacture and marketing of human and veterinary medicines as well as diagnostic tests. The company’s core therapeutic areas include central nervous system disorders, oncology and respiratory diseases, and it offers both proprietary and generic products. Orion’s product range spans from small-molecule drugs and active pharmaceutical ingredients to radiodiagnostic imaging agents and line extensions developed through in-house research.

Since its founding in 1917 in Helsinki, Orion has grown into an integrated pharmaceuticals business with state-of-the-art manufacturing facilities in Finland and France.